FY27 growth to return to historical CAGR of ~18%
Management expects FY27 performance to normalize to historical growth rates of around 18%, driven by recovery in core API and injectable ramp-up.
CONCORDBIO / guidance tracker
Keep management guidance in view.
Concord Biotech · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
growth
Injectable facility peak revenue potential of ₹600 crore
The injectable facility, now WHO GMP certified, has a peak revenue potential of approximately ₹600 crore, with initial focus on domestic market.
Maintenance capex of ₹100-150 crore annually
Annual capex is expected to be in the range of ₹100-150 crore, including maintenance and growth projects.